Mobile

An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004810-41

An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with genotype 1 chronic hepatitis C

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of boceprevir in triple combination therapy with peginterferon alfa-2a and ribavirin given as response guided treatment regimen (total of 28 or 48 treatment weeks) on the clearance of HCV 12 weeks after treatment end (sustained virological response) in treatment-naïve patients with genotype 1 chronic HCV infection

Critère d'inclusion

  • Genotype 1 CHC virus infection

Liens